News >

FDA Grants Pembrolizumab Priority Review for High-Risk NMIBC

Gina Columbus @ginacolumbusonc
Published: Monday, Dec 02, 2019

Dr. Roy Baynes

Roy Baynes, MD, PhD
The FDA has granted a priority review designation to pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication